A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer.

Tiffany M JuarezJaya M GillAnnie HengJose A CarrilloNaveed WagleNatsuko NomuraMinhdan NguyenJudy TruongLucia DobrawaWalavan SivakumarGarni BarkhoudarianDaniel F Kelly Santosh Kesari

Published in: Neuro-oncology advances (2024)

Afatinib taken orally was safe and well-tolerated up to 280 mg every 7 days in brain cancer patients.

Keyphrases

resting state
white matter
multiple sclerosis
epidermal growth factor receptor
functional connectivity
papillary thyroid
advanced non small cell lung cancer
open label
randomized controlled trial
clinical trial
squamous cell carcinoma
young adults
study protocol